Akebia Therapeutics, Inc.
NASDAQ:AKBA · NASDAQ Global Market
+$0.01 today
Vol 22.76M · Avg 4.03M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$5.3M +92.3% | -$69.4M -33.7% | -$51.9M +43.9% | -$92.6M +67.2% | -$282.0M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $1.3M -96.6% | $37.5M -10.4% | $41.8M +11.0% | $37.7M +4.3% | $36.1M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $11.3M +45.1% | $7.8M -16.6% | $9.3M -47.8% | $17.8M -21.5% | $22.7M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | $16.5M +141.5% | -$39.7M -91.4% | -$20.7M -1344.4% | -$1.4M +98.6% | -$105.6M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$14.1M -449.5% | $4.0M +307.0% | $994.0K -91.5% | $11.7M +148.7% | -$24.0M | $592.6M | $1.3B | $626.2M |
| Inventory | -$23.1M +18.6% | -$28.4M -1017.3% | -$2.5M -112.8% | $19.8M +179.3% | -$24.9M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $3.1M +326.0% | -$1.4M +74.0% | -$5.2M -449.4% | $1.5M +112.8% | -$11.7M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $50.7M +463.0% | -$14.0M -0.2% | -$13.9M +59.5% | -$34.4M +23.3% | -$44.9M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $44.3M +91.4% | $23.1M +1321.5% | -$1.9M +94.5% | -$34.7M -135.2% | $98.5M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $68.0M +267.2% | -$40.7M -73.9% | -$23.4M +68.0% | -$73.2M +71.1% | -$253.0M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$291.0K -781.8% | -$33.0K | $0 +100.0% | -$114.0K -93.2% | -$59.0K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 | $0 | $0 -100.0% | $40.0M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$7.9M | $0 | $0 | $0 | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$7.9M -23918.2% | -$33.0K | $0 +100.0% | -$114.0K -100.3% | $39.9M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $4.6M -41.4% | $7.9M +124.7% | -$32.0M +3.0% | -$33.0M -173.7% | $44.8M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $68.4M +60.3% | $42.6M +527.8% | $6.8M -9.8% | $7.5M -91.5% | $88.9M | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 +100.0% | -$1.3M | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$63.0K -116.4% | $385.0K +38400.0% | $1.0K -100.0% | $40.1M | $0 | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $72.9M +46.8% | $49.7M +297.0% | -$25.2M -272.7% | $14.6M -89.1% | $133.7M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 | $0 | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $133.0M +1382.5% | $9.0M +118.5% | -$48.6M +17.2% | -$58.7M +26.0% | -$79.3M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $68.0M +267.1% | -$40.7M -74.0% | -$23.4M +68.1% | -$73.3M +71.0% | -$253.0M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
$1.44B
Ventyx Biosciences, Inc.
VTYX
$1.00B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$993.02M
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$801.81M
Zevra Therapeutics, Inc.
NASDAQ:ZVRA
$763.10M
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
$606.88M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$501.07M
Prothena Corporation plc
NASDAQ:PRTA
$463.33M
Compass Therapeutics, Inc.
NASDAQ:CMPX
$280.72M
Gossamer Bio, Inc.
GOSS
$39.47M
SEC Filings
Recent regulatory filings
No filings found.
Does AKBA generate free cash flow?
Akebia Therapeutics, Inc. (AKBA) generated $67.99M of free cash flow in fiscal 2025.
How much operating cash flow does AKBA produce?
Operating cash flow was $67.99M, before capital expenditures of $291,000.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.